Ideas

Empagliflozin-based Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients: Empagliflozin(EMBA) (Brand name: Jardiance), a drug used in the treatment of TIIDM, increases the expression of ERBB2/Her2 and promotes dedifferentiation  of cardiomyocytes, via up-regulation of its target gene, 14/February/2018, 10.54 pm
Empagliflozin-based Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients: Empagliflozin(EMBA) (Brand name: Jardiance), a drug used in the treatment of TIIDM, increases the expression of ERBB2/Her2 and promotes dedifferentiation  of cardiomyocytes, via up-regulation of its target gene, 14/February/2018, 10.54 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A recent study from the Department of Biological Regulation, Weizmann Institute of Science, Rehovot 76100, Israel shows that “ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation.” This study was published, in the 6 April…

read more

Ribonucleic acid-based therapy for aging-associated diseases and Lifespan extension: LncRNA DANCR  inhibits the interaction of DBC1 with PARP1, increases the PARP1 activity, promotes DNA repair, augments tolerance against radiation, cancer, and aging, via down-regulation of its target gene, 14/February/2019, 6.48 am
Ribonucleic acid-based therapy for aging-associated diseases and Lifespan extension: LncRNA DANCR  inhibits the interaction of DBC1 with PARP1, increases the PARP1 activity, promotes DNA repair, augments tolerance against radiation, cancer, and aging, via down-regulation of its target gene, 14/February/2019, 6.48 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from Department of Genetics, Paul F. Glenn Center for the Biology of Aging, Harvard Medical School, Boston, MA, USA; and Department of Pharmacology, School…

read more

Immune enhancement therapy: Ezetimibe, a drug used in the treatment of dyslipidemia, increases SOX2 expression, and promotes innate immunity against bacterial infection, via down-regulation of its target gene, 14/February/2019, 6.41 am
Immune enhancement therapy: Ezetimibe, a drug used in the treatment of dyslipidemia, increases SOX2 expression, and promotes innate immunity against bacterial infection, via down-regulation of its target gene, 14/February/2019, 6.41 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say:   A recent study from the Institute of Biophysics, Chinese Academy of Sciences, Beijing, China shows that “Sox2 functions as a sequence-specific DNA sensor in neutrophils to initiate innate…

read more

Combinatorial therapy for gynecologic cancers: A therapeutic mix encompassing Simvastatin and Navitoclax (ABT-263) (SAN) inhibits the expression of HDAC6, acetylates tumor suppressor proteins, activates tumor suppressor function, and stifles the progression of ARID1A-mutated ovarian cancers, via up-regulation of its target gene, 14/February/2019, 6.29 am
Combinatorial therapy for gynecologic cancers: A therapeutic mix encompassing Simvastatin and Navitoclax (ABT-263) (SAN) inhibits the expression of HDAC6, acetylates tumor suppressor proteins, activates tumor suppressor function, and stifles the progression of ARID1A-mutated ovarian cancers, via up-regulation of its target gene, 14/February/2019, 6.29 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say:  A study from Gene Expression and Regulation Program, The Wistar Institute, Philadelphia, Pennsylvania 19104, USA shows that “ARID1A-mutated ovarian cancers depend on HDAC6 activity” This study…

read more

Molecular therapy for Malaria: Probucol, a drug used in the treatment of dyslipidemia, increases Ferroportin expression, decreases intracellular iron accumulation, inhibits cellular damage, prevents hemolysis, and inhibits malaria infection, via upregulation of its target gene, 14/February/2019, 6.21 am
Molecular therapy for Malaria: Probucol, a drug used in the treatment of dyslipidemia, increases Ferroportin expression, decreases intracellular iron accumulation, inhibits cellular damage, prevents hemolysis, and inhibits malaria infection, via upregulation of its target gene, 14/February/2019, 6.21 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A study from the Section on Human Iron Metabolism, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD…

read more

Ribonucleic acid-based therapy for aging-associated diseases and Lifespan extension: LncRNA PCGEM1 (Prostate-specific transcript 1)  inhibits the interaction of DBC1 with PARP1, increases the PARP1 activity, promotes DNA repair, augments tolerance against radiation, cancer, and ageing, via down-regulation of its target gene, 12/February/2019, 11.14 pm
Ribonucleic acid-based therapy for aging-associated diseases and Lifespan extension: LncRNA PCGEM1 (Prostate-specific transcript 1)  inhibits the interaction of DBC1 with PARP1, increases the PARP1 activity, promotes DNA repair, augments tolerance against radiation, cancer, and ageing, via down-regulation of its target gene, 12/February/2019, 11.14 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from Department of Genetics, Paul F. Glenn Center for the Biology of Aging, Harvard Medical School, Boston, MA, USA; and Department of Pharmacology, School…

read more
Start Typing